carboplatin + paclitaxel + cisplatin

This treatment protocol, evaluated in a Phase II randomized clinical trial (NCT02124421) at Mercy Medical Center, investigates the efficacy and toxicity of various chemotherapy combinations in patients with newly diagnosed advanced (Stage III/IV) ovarian, fallopian tube, and primary peritoneal cancer. The regimen involves cytoreductive surgery (CRS) followed by either carboplatin-based hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic adjuvant carboplatin/paclitaxel, or a combination of intraperitoneal and intravenous cisplatin/paclitaxel. Carboplatin and cisplatin are platinum-containing small molecules that act as DNA alkylating agents, forming intra- and inter-strand cross-links that inhibit DNA synthesis and lead to apoptosis. Paclitaxel is a taxane that binds to and stabilizes microtubules, preventing their depolymerization and thereby arresting the cell cycle in the G2/M phase.

Other names

adjuvant chemotherapy-Mercy Medical Center-ovarian cancer-fallopian tube cancer-primary peritoneal carcinomaCRS with/without Carboplatin HIPEC in Advanced Ovarian Cancer